Lab studies suggest that the Pfizer–BioNTech and Moderna COVID-19 vaccines are significantly less effective in providing antibody protection against the 501.V2 variant of the disease, which is most prevalent in South Africa. (The Guardian) COVID-19 vaccine, Variants of SARS-CoV-2COVID-19 pandemic link embed save